InnoCare Starts US Trial of BTK Inhibitor for MS

Beijing 's InnoCare Pharma was approved to start a US Phase II trial of orelabrutinib, a Bruton’s tyrosine kinase inhibitor, in patients with multiple sclerosis. The trial will enroll 160 patients with relapsing-remitting MS in the US and several EU countries. Orelabrutinib is already being tested in the US and China as a treatment for B-cell lymphomas and autoimmune indications as a monotherapy or in combination regimens. InnoCare says it has shown efficacy with an ability to cross the blood-brain barrier. More details.... Stock Symbol: (HK: 09969) Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.